ABSTRACT
Objective To analyze and compare the application results of glibenclamide and insulin in treating gestational diabetes mellitus (GDM). Methods The subjects of this study were selected from 68 cases of pregnant women with GDM admitted in our hospital from September 2015 to March 2017. They were randomly divided into the control group (insulin) and the observation group (glibenclamide), each with 34 cases. The clinical efficacy and adverse pregnancy outcomes were compared between the two groups. Results The fasting blood-glucose (FBG), 2 h postprandial plasma glucose (2 h PG), and glycosylated hemoglobin (HbA1c) levels of both groups after treatment decreased significantly (P<0.05), but there was no big difference in the above indexes between the two groups after treatment. The incidence of fetal macrosomia, fetal asphyxia and neonatal hypoglycemia in the observation group was 17.65%, 23.53% and 20.59% respectively, much higher than that in the control group (P<0.05). Conclusion In treating GDM, both glibenclamide and insulin are effective in enabling better blood-glucose control, but insulin has an advantage over the other in improving pregnancy outcomes. With the informed consent of some GDM patients, oral hypoglycemic agents can be used with caution.
ABSTRACT
Objective To analyze and compare the application results of glibenclamide and insulin in treating gestational diabetes mellitus (GDM). Methods The subjects of this study were selected from 68 cases of pregnant women with GDM admitted in our hospital from September 2015 to March 2017. They were randomly divided into the control group (insulin) and the observation group (glibenclamide), each with 34 cases. The clinical efficacy and adverse pregnancy outcomes were compared between the two groups. Results The fasting blood-glucose (FBG), 2 h postprandial plasma glucose (2 h PG), and glycosylated hemoglobin (HbA1c) levels of both groups after treatment decreased significantly (P<0.05), but there was no big difference in the above indexes between the two groups after treatment. The incidence of fetal macrosomia, fetal asphyxia and neonatal hypoglycemia in the observation group was 17.65%, 23.53% and 20.59% respectively, much higher than that in the control group (P<0.05). Conclusion In treating GDM, both glibenclamide and insulin are effective in enabling better blood-glucose control, but insulin has an advantage over the other in improving pregnancy outcomes. With the informed consent of some GDM patients, oral hypoglycemic agents can be used with caution.